This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

• BMO Capital analyst Evan Seigerman downgraded the rating for Biogen Inc. BIIB from Outperform to Market Perform and lowered the price target from $230 to $164. Biogen shares closed at $147.39 on Thursday. See how other analysts view this stock.
• Telsey Advisory Group analyst Cristina Fernandez downgraded NIKE, Inc. NKE from Outperform to Market Perform and slashed the price target from $93 to $80. Nike shares closed at $77.10 on Thursday. See how other analysts view this stock.
• Stifel analyst Thomas Stephan downgraded the rating for RxSight, Inc. RXST from Buy to Hold and lowered the price target from $65 to $40. RxSight shares closed at $38.19 on Thursday. See how other analysts view this stock.
• Keefe, Bruyette & Woods analyst Aidan Hall downgraded Lazard, Inc. LAZ from Outperform to Market Perform and cut the price target from $65 to $57. Lazard shares closed at $50.49 on Thursday. See how other analysts view this stock.
• Citigroup analyst Thomas Palmer downgraded Lamb Weston Holdings, Inc. LW from Buy to Neutral and lowered the price target from $90 to $68. Lamb Weston shares closed at $62.50 on Thursday. See how other analysts view this stock.

Considering buying NKE stock? Here’s what analysts think:

Read This Next:

• Jim Cramer Likes Walmart, Recommends Buying This ‘Very, Very Good’ Financial Stock